Der Maus Monoklonal Anti-s100a4-Antikörper wurde für FACS, EIA, ELISA (Capture) und ELISA (Detection) validiert. Er ist geeignet, s100a4 in Proben von Human zu detektieren.
Recognizes Human S100 Calcium Binding Protein A4 (S100A4). Other species not tested.
Aufreinigung
Affinity Chromatography on Protein G
Immunogen
Genetic immunisation with cDNA encoding S100A4. Selection: based on recognition of the complete native protein expressed on transfected mammalian cells.
Flow cytometry: 1.2 μg/10 6 cells. ELISA: 1/200-1/400. ELISA (capture): Clone NJ-4F3-D1 as detection antibody. ELISA (detection): Clone NJ-5C6-A3 as capture antibody. Cell based ELISA with intakt, transiently transfected cells: 1/200-1/400.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Phosphate buffered saline, pH 7.2
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
Haltbarkeit
12 months
Target
s100a4 (S100A4)
(S100 Calcium Binding Protein A4 (S100A4))
Andere Bezeichnung
s100a4
Hintergrund
S100 calcium binding protein A4 (S100A4) is a member of the S100 family of calcium-binding proteins that contain two Ca(2+)-binding sites including a canonical EF-hand motif. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells. S100A4 interacts with cytoskeletal proteins and enhances metastasis of several types of cancer cells. It is secreted by unknown mechanisms, thus, paracrinely stimulating a variety of cellular responses, including angiogenesis and neuronal growth (1). S100A4 has been shown to be a prognostic marker in a number of human cancers, including esophageal-squamous cancers, non-small lung cancers, primary gastric cancers, malignant melanomas, prostate cancers, bladder cancers, and pancreatic carcinomas. The universality of S100A4 expression in a variety of cancers illustrates the potential use of S100A4 as a marker for tumor metastasis and disease progression (2).